Cannabis Sativa

Content deleted Content added
Bon courage (talk | contribs)
Restored revision 1176523432 by Tosha Langue (talk): Wrong
Citation bot (talk | contribs)
Removed parameters. | Use this bot. Report bugs. | Suggested by Susmuffin | Category:CS1 maint: PMC embargo expired | #UCB_Category 1/4
(40 intermediate revisions by 23 users not shown)
Line 1: Line 1:
{{Short description|Drug, supplement, or other substance that improves cognitive function}}
{{Short description|Compound intended to improve cognitive function}}
{{cs1 config|name-list-style=vanc}}
{{Update|date=June 2022}}
{{Use mdy dates|date=March 2023}}
{{Use mdy dates|date=March 2023}}
{{multiple image
{{multiple image
Line 9: Line 9:
<!-- Extra parameters -->
<!-- Extra parameters -->
| image1 = Coffea arabica - Köhler–s Medizinal-Pflanzen-189.jpg
| image1 = Coffea arabica - Köhler–s Medizinal-Pflanzen-189.jpg
| caption1 = [[Caffeine]] is the world's most consumed nootropic, from the ''[[Coffea arabica]]'' plant.
| caption1 = [[Caffeine]] from the ''[[Coffea arabica]]'' plant is the world's most consumed nootropic.
| alt1 = Illustration of Coffea arabica plant and seeds
| alt1 = Illustration of Coffea arabica plant and seeds
| image2 =
| image2 =
Line 16: Line 16:
}}
}}


'''Nootropics''' ({{IPAc-en|n|oʊ|.|ə|ˈ|t|r|oʊ|p|ᵻ|k|s}} {{respell|noh|ə|TROHP|iks}} or {{IPAc-en|n|oʊ|.|ə|ˈ|t|r|ɒ|p|ᵻ|k|s}} {{respell|noh|ə|TROP|iks}}<ref name="Lexico">{{Cite encyclopedia |title=Nootropic |url=https://www.lexico.com/definition/nootropic|archive-url=https://web.archive.org/web/20200929201325/https://www.lexico.com/definition/nootropic|url-status=dead|archive-date=September 29, 2020|access-date=July 3, 2021|encyclopedia=Lexico Dictionaries |language=en}}</ref>) ([[colloquial]]: '''brain supplements''', '''smart drugs''' and '''cognitive enhancers''') are numerous natural, semi-synthetic and synthetic [[molecules]] that claim to improve [[cognitive functions]] (such as [[executive functions]], [[attention]], [[memory]], creativity).
'''Nootropics''' ({{IPAc-en|n|oʊ|.|ə|ˈ|t|r|oʊ|p|ᵻ|k|s}} {{respell|noh|ə|TROHP|iks}} or {{IPAc-en|n|oʊ|.|ə|ˈ|t|r|ɒ|p|ᵻ|k|s}} {{respell|noh|ə|TROP|iks}};<ref name="Lexico">{{cite encyclopedia |title=Nootropic |url=https://www.oed.com/search/advanced/Meanings?scope=HistoricalThesaurus&q=nootropic|encyclopedia=Oxford English Dictionary|date=2024|accessdate=14 January 2024 |language=en}}</ref> but not {{IPAc-en|n|j|uː|ˈ|t|r|oʊ|p|ᵻ|k|s}} {{respell|new|TROHP|iks}} or {{IPAc-en|n|j|uː|ˈ|t|r|ɒ|p|ᵻ|k|s}} {{respell|new|TROP|iks}},<ref name="Lexico">{{cite encyclopedia |title=Nootropic |url=https://www.oed.com/search/advanced/Meanings?scope=HistoricalThesaurus&q=nootropic|encyclopedia=Oxford English Dictionary|date=2024|accessdate=14 January 2024 |language=en}}</ref> which are common mispronunciations), colloquially '''brain supplements''', '''smart drugs''' and '''cognitive enhancers''', are natural, semisynthetic or synthetic [[Chemical compound|compounds]] which purportedly improve [[cognitive function]]s, such as [[executive functions]], [[attention]] or [[memory]].


While often found in the form of [[dietary supplements]], [[nutraceuticals]] and [[energy drinks]],<ref name="NeuroClin"/> some nootropic molecules can also be found as prescription and non-prescription [[pharmaceutical drugs]] in various countries.
While commonly in the form of [[dietary supplement]]s, [[nutraceutical]]s or [[energy drink]]s,<ref name="NeuroClin"/> some nootropic compounds are [[prescription drug|prescription]] and non-prescription drugs in various countries.


In the United States, the [[Federal Trade Commission]] and [[Food and Drug Administration|FDA]] have warned manufacturers and consumers about possible [[fraud|advertising fraud]] and [[Confidence trick|marketing scams]] concerning nootropic supplements.<ref name="ftc" /><ref name="fda-fraud" />
==History and definition==
The term ''nootropic'' is derived {{ety|grc|''{{wikt-lang|grc|νόος}}'' (nóos)|mind||''{{wikt-lang|grc|τροπή}}'' (tropḗ)|turning}}.<ref name="Lexico"/><ref name="Giurgea1977">{{Cite journal| vauthors = Giurgea C, Salama M |date=January 1, 1977|title=Nootropic drugs|journal=Progress in Neuro-Psychopharmacology |volume=1 |issue=3 |pages=235–247 |doi=10.1016/0364-7722(77)90046-7 |quote=The term "nootropic" (noos = mind; tropein = towards) was proposed by us (Giurgea, 1972,1973) to designate psychotropic drugs}}</ref><ref name="Giurgea1972">{{cite journal | vauthors = Giurgea C | title = [Pharmacology of integrative activity of the brain. Attempt at nootropic concept in psychopharmacology] | language = fr | journal = Actualites Pharmacologiques | volume = 25 | pages = 115–156 | date = 1972 | pmid = 4541214 }}</ref>


==History of term==
The first documented use of "nootropic" in reference to substances purported to increase cognitive functions was by [[Corneliu E. Giurgea]] in 1972/1973.<ref name="malik">{{cite journal | vauthors = Malík M, Tlustoš P | title = Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs | journal = Nutrients | volume = 14 | issue = 16 | page = 3367 | date = August 2022 | pmid = 36014874 | pmc = 9415189 | doi = 10.3390/nu14163367 | doi-access = free }}</ref> When researching a new compound, Giurgea found a spectrum of effects that did not align with any psychotropic drug category, leading to his proposal of a new category and the conception of the term nootropic.
The term ''nootropic'' is derived {{ety|grc|''{{wikt-lang|grc|νόος}}'' (nóos)|mind||''{{wikt-lang|grc|τροπή}}'' (tropḗ)|turning}}.<ref name="Lexico"/><ref name="Giurgea1972">{{cite journal | vauthors = Giurgea C | title = [Pharmacology of integrative activity of the brain. Attempt at nootropic concept in psychopharmacology] | language = fr | journal = Actualites Pharmacologiques | volume = 25 | pages = 115–156 | date = 1972 | pmid = 4541214 }}</ref><ref name="Giurgea1977">{{cite journal| vauthors = Giurgea C, Salama M |date=January 1, 1977|title=Nootropic drugs|journal=Progress in Neuro-Psychopharmacology |volume=1 |issue=3 |pages=235–247 |doi=10.1016/0364-7722(77)90046-7 |quote=The term "nootropic" (noos = mind; tropein = towards) was proposed by us (Giurgea, 1972,1973) to designate psychotropic drugs}}</ref>


The first documented use of "nootropic" in reference to substances purported to increase cognitive functions was by [[Corneliu E. Giurgea]] in 1972.<ref name="Giurgea1972"/><ref name="Giurgea1977"/><ref name="malik">{{cite journal | vauthors = Malík M, Tlustoš P | title = Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs | journal = Nutrients | volume = 14 | issue = 16 | page = 3367 | date = August 2022 | pmid = 36014874 | pmc = 9415189 | doi = 10.3390/nu14163367 | doi-access = free }}</ref> When researching a new compound, Giurgea found a spectrum of effects that did not align with any psychotropic drug category, leading to his proposal of a new category and the concept of the term nootropic.<ref name="Giurgea1977"/>
Guirgea stated that nootropic drugs should have the following characteristics:

Giurgea stated that nootropic drugs should have the following characteristics:


# They should enhance [[learning]] and [[memory]].
# They should enhance [[learning]] and [[memory]].
# They should enhance the resistance of learned behaviors/memories to conditions which tend to disrupt them (e.g. [[electroconvulsive shock]], [[hypoxia (medical)|hypoxia]]).
# They should enhance the resistance of learned behaviors or memories to conditions which tend to disrupt them (e.g. [[electroconvulsive shock]], [[hypoxia (medical)|hypoxia]]).
# They should protect the brain against various physical or chemical injuries (e.g. [[barbiturate]]s, [[scopalamine]]).
# They should protect the brain against various physical or chemical injuries.
# They should increase the efficacy of the tonic cortical/subcortical control mechanisms.
# They should increase the efficacy of the tonic [[cerebral cortex|cortical]] control mechanisms.
# They should lack the usual pharmacology of other [[psychotropic]] drugs (e.g. [[sedation]], motor stimulation) and possess very few [[adverse effect|side effect]]s and extremely low [[toxicity]].
# They should lack the usual pharmacology of other [[psychotropic]] drugs (e.g. [[sedation]], motor stimulation) and possess few [[adverse effect]]s and low [[toxicity]].


However, there is no globally accepted or clinical definition of a nootropic. Most compounds described as nootropic do not correspond to Giurgea's characteristics.<ref name="malik" />
While the term has seen decades of use in clinical and scientific contexts, colloquial use often refers to compounds outside the bounds of Guirgea's characteristics; example of this broadening include many of the compounds listed below. Part of this confusion stems from citations of there being no globally accepted uniform or standard approach for categorizing nootropic substances and compounds.<ref name="malik" />


==Marketing claims==
==Unproven marketing claims==
In the United States, Nootropics are often advertised with unproven claims of effectiveness for improving cognition. Manufacturers' marketing claims for [[dietary supplements]] are usually not formally tested and verified by independent entities.<ref>{{cite web|title=Dietary Supplements: What You Need to Know|url=https://www.fda.gov/Food/DietarySupplements/UsingDietarySupplements/ucm109760.htm|publisher=US Food and Drug Administration|access-date=February 14, 2015}}</ref> The US [[Food and Drug Administration]] (FDA) and [[Federal Trade Commission]] (FTC) [[FDA warning letter|warned]] manufacturers and consumers in 2019 about possible advertising fraud and marketing scams concerning nootropic supplement products.<ref name="ftc">{{Cite web |date=February 11, 2019 |title=FTC and FDA Send Warning Letters to Companies Selling Dietary Supplements Claiming to Treat Alzheimer's Disease and Remediate or Cure Other Serious Illnesses Such as Parkinson's, Heart Disease, and Cancer |url=https://www.ftc.gov/news-events/press-releases/2019/02/ftc-fda-send-warning-letters-companies-selling-dietary |access-date=May 11, 2019 |publisher=US Food and Drug Administration, US Federal Trade Commission}}</ref><ref name="fda-fraud">{{Cite web |date=December 22, 2018 |title=Health fraud scams: Unproven Alzheimer's disease products |url=https://www.fda.gov/consumers/health-fraud-scams/unproven-alzheimers-disease-products |access-date=May 11, 2019 |publisher=US Food and Drug Administration}}</ref><ref name="fda">{{Cite web |url=https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-nootropics-llc-aka-advanced-nootropics-565256-02052019 |title=FDA Warning Letter: Peak Nootropics LLC aka Advanced Nootropics | vauthors = Correll Jr WA |date=February 5, 2019 |publisher=Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration |access-date=May 11, 2019}}</ref><ref name="fda2">{{Cite web |url=https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tek-naturals-565026-02042019 |title=FDA Warning Letter: TEK Naturals | vauthors = Correll Jr WA |date=February 5, 2019 |publisher=Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration |access-date=May 11, 2019}}</ref> The FDA and FTC stated that some nootropic products had not been [[drug approval|approved]] as a [[prescription drug|drug]] effective for any medical purpose, were not proven to be safe, and were illegally marketed in the United States under violation of the [[Federal Food, Drug, and Cosmetic Act]].<ref name=ftc/><ref name=fda-fraud/>
In the United States, nootropics are commonly advertised with unproven claims of effectiveness for improving cognition. Manufacturers' marketing claims for dietary supplements are usually not formally tested and verified by independent entities.<ref>{{cite web|title=Dietary Supplements: What You Need to Know|url=https://www.fda.gov/Food/DietarySupplements/UsingDietarySupplements/ucm109760.htm|publisher=US Food and Drug Administration|access-date=February 14, 2015}}</ref> In 2019, the US FDA and [[Federal Trade Commission|FTC]] [[FDA warning letter|warned]] manufacturers and consumers about possible advertising fraud and marketing scams concerning nootropic supplement products.<ref name="ftc">{{cite web |date=February 11, 2019 |title=FTC and FDA Send Warning Letters to Companies Selling Dietary Supplements Claiming to Treat Alzheimer's Disease and Remediate or Cure Other Serious Illnesses Such as Parkinson's, Heart Disease, and Cancer |url=https://www.ftc.gov/news-events/press-releases/2019/02/ftc-fda-send-warning-letters-companies-selling-dietary |access-date=May 11, 2019 |publisher=US Food and Drug Administration, US Federal Trade Commission}}</ref><ref name="fda-fraud">{{cite web |date=December 22, 2018 |title=Health fraud scams: Unproven Alzheimer's disease products |url=https://www.fda.gov/consumers/health-fraud-scams/unproven-alzheimers-disease-products |access-date=May 11, 2019 |publisher=US Food and Drug Administration}}</ref><ref name="fda">{{cite web |url=https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-nootropics-llc-aka-advanced-nootropics-565256-02052019 |title=FDA Warning Letter: Peak Nootropics LLC aka Advanced Nootropics | vauthors = Correll Jr WA |date=February 5, 2019 |publisher=Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration |access-date=May 11, 2019}}</ref><ref name="fda2">{{cite web |url=https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tek-naturals-565026-02042019 |title=FDA Warning Letter: TEK Naturals | vauthors = Correll Jr WA |date=February 5, 2019 |publisher=Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration |access-date=May 11, 2019}}</ref> The FDA and FTC stated that some nootropic products had not been [[drug approval|approved]] as a prescription drug effective for any medical purpose, were not proven to be safe, and were illegally marketed in the United States under violation of the [[Federal Food, Drug, and Cosmetic Act]].<ref name=ftc/><ref name=fda-fraud/>


In 2018 in the United States, some nootropic supplements were identified as having misleading ingredients and illegal marketing.<ref name="schultz">{{Cite web | vauthors = Schultz H |date=May 17, 2018 |title=Some shady ingredients find home in nootropics category |url=https://www.nutraingredients-usa.com/Article/2018/05/17/Some-shady-ingredients-find-home-in-nootropics-category# |access-date=May 11, 2019 |publisher=NutraIngredients-USA.com, William Reed Business Media Ltd}}</ref><ref name="heid">{{Cite web | vauthors = Heid M |date=January 23, 2019 |title=Nootropics, or 'Smart Drugs,' Are Gaining Popularity. But Should You Take Them? |url=http://time.com/5509993/nootropics-smart-drugs-brain/ |access-date=May 12, 2019 |publisher=Time}}</ref> In 2019, the FDA and FTC warned manufacturers and consumers about possible [[fraud|advertising fraud]] and [[Confidence trick|marketing scams]] concerning nootropic supplements.<ref name="ftc" /><ref name="fda-fraud" />
In 2018 in the United States, some nootropic supplements were identified as having misleading ingredients and illegal marketing.<ref name="schultz">{{cite web | vauthors = Schultz H |date=May 17, 2018 |title=Some shady ingredients find home in nootropics category |url=https://www.nutraingredients-usa.com/Article/2018/05/17/Some-shady-ingredients-find-home-in-nootropics-category# |access-date=May 11, 2019 |publisher=NutraIngredients-USA.com, William Reed Business Media Ltd}}</ref><ref name="heid">{{cite web | vauthors = Heid M |date=January 23, 2019 |title=Nootropics, or 'Smart Drugs,' Are Gaining Popularity. But Should You Take Them? |url=http://time.com/5509993/nootropics-smart-drugs-brain/ |access-date=May 12, 2019 |publisher=Time}}</ref> In 2019, the FDA and FTC warned manufacturers and consumers about possible advertising fraud and marketing scams concerning nootropic supplements.<ref name="ftc" /><ref name="fda-fraud" />


Over the years 2010 to 2019, the FDA warned numerous supplement manufacturers about the illegal status of their products as unapproved drugs with no proven safety or efficacy at the doses listed on the products, together with misleading marketing.<ref name="ftc" /><ref name="fda-fraud" /><ref name="fda" /><ref name="fda2" /><ref name="cerebral">{{Cite web |url=https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2010/ucm198452.htm |archive-url=https://wayback.archive-it.org/7993/20170112195041/https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2010/ucm198452.htm |url-status=dead |archive-date=January 12, 2017 |title=FDA Warning Letter: Cerebral Health LLC | vauthors = Singleton ER |date=January 7, 2010 |publisher=Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration |access-date=May 12, 2019}}</ref><ref name="unlimited" />
Over the years 2010 to 2019, the FDA warned numerous supplement manufacturers about the illegal status of their products as unapproved drugs with no proven safety or efficacy at the doses listed on the products, together with misleading marketing.<ref name="ftc" /><ref name="fda-fraud" /><ref name="fda" /><ref name="fda2" /><ref name="cerebral">{{cite web |url=https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2010/ucm198452.htm |archive-url=https://wayback.archive-it.org/7993/20170112195041/https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2010/ucm198452.htm |url-status=dead |archive-date=January 12, 2017 |title=FDA Warning Letter: Cerebral Health LLC | vauthors = Singleton ER |date=January 7, 2010 |publisher=Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration |access-date=May 12, 2019}}</ref><ref name="unlimited" />


== Availability and prevalence ==
== Availability and prevalence ==
In 2008, the most commonly used class of drug was [[stimulants]], such as [[caffeine]].<ref name="Nature2008">{{cite journal | vauthors = Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, Farah MJ | title = Towards responsible use of cognitive-enhancing drugs by the healthy | journal = Nature | volume = 456 | issue = 7223 | pages = 702–705 | date = December 2008 | pmid = 19060880 | doi = 10.1038/456702a | s2cid = 3598099 | bibcode = 2008Natur.456..702G | oclc = 01586310 | url = https://pure.manchester.ac.uk/ws/files/28322116/POST-PEER-REVIEW-PUBLISHERS.PDF }}</ref> In 2016, the [[American Medical Association]] adopted a policy to discourage [[prescription drug|prescriptions]] of nootropics for healthy people, on the basis that the cognitive effects appear to be highly variable among individuals, are dose-dependent, and limited or modest at best.<ref name="ama">{{cite web |title=AMA confronts the rise of nootropics |url=https://www.ama-assn.org/press-center/press-releases/ama-confronts-rise-nootropics |publisher=American Medical Association |access-date=May 12, 2019 |date=June 14, 2016}}</ref> More recently piracetam, noopept and meclofenoxate have been sold as dietary supplements.<ref name="JAMAIM"/><ref name="NeuroClin"/><ref>{{cite journal | vauthors = Cohen PA, Avula B, Khan I | title = The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements | journal = Clinical Toxicology | volume = 60 | issue = 10 | pages = 1156–1158 | date = October 2022 | pmid = 35959800 | doi = 10.1080/15563650.2022.2109485 | s2cid = 251516603 }}</ref>
In 2008, stimulants, such as caffeine, were the most commonly used nootropic agent.<ref name="Nature2008">{{cite journal | vauthors = Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, Farah MJ | title = Towards responsible use of cognitive-enhancing drugs by the healthy | journal = Nature | volume = 456 | issue = 7223 | pages = 702–705 | date = December 2008 | pmid = 19060880 | doi = 10.1038/456702a | s2cid = 3598099 | bibcode = 2008Natur.456..702G | oclc = 01586310 | url = https://pure.manchester.ac.uk/ws/files/28322116/POST-PEER-REVIEW-PUBLISHERS.PDF }}</ref> In 2016, the [[American Medical Association]] adopted a policy to discourage prescriptions of nootropics for healthy people, on the basis that the cognitive effects appear to be highly variable among individuals, are dose-dependent, and limited or modest at best.<ref name="ama">{{cite web |title=AMA confronts the rise of nootropics |url=https://www.ama-assn.org/press-center/press-releases/ama-confronts-rise-nootropics |publisher=American Medical Association |access-date=May 12, 2019 |date=June 14, 2016}}</ref> [[Piracetam]], [[N-Phenylacetyl-L-prolylglycine ethyl ester|noopept]] and [[meclofenoxate]] have been sold as dietary supplements.<ref name="NeuroClin"/><ref name="JAMAIM"/><ref>{{cite journal | vauthors = Cohen PA, Avula B, Khan I | title = The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements | journal = Clinical Toxicology | volume = 60 | issue = 10 | pages = 1156–1158 | date = October 2022 | pmid = 35959800 | doi = 10.1080/15563650.2022.2109485 | s2cid = 251516603 }}</ref>


==Side effects==
==Adverse effects==
The main concern with [[pharmaceutical drug]]s and dietary supplements are [[adverse effect]]s. Long-term safety evidence is typically unavailable for many nootropic compounds. [[Racetams]], [[piracetam]] and other compounds that are structurally related to piracetam, have few serious adverse effects and low [[toxicity]], but there is little evidence that they enhance cognition in people having no cognitive impairments.<ref name="Racetam efficacy review 2010">{{cite journal | vauthors = Malykh AG, Sadaie MR | title = Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders | journal = Drugs | volume = 70 | issue = 3 | pages = 287–312 | date = February 2010 | pmid = 20166767 | doi = 10.2165/11319230-000000000-00000 | s2cid = 12176745 }}</ref>
The main concern with [[pharmaceutical drug]]s and dietary supplements are [[adverse effect]]s. Long-term safety evidence is typically unavailable for many nootropic compounds. [[Racetams]], piracetam and other compounds that are structurally related to piracetam, have few serious adverse effects and low [[toxicity]], but there is little evidence that they enhance cognition in people having no cognitive impairments.<ref name="Racetam efficacy review 2010">{{cite journal | vauthors = Malykh AG, Sadaie MR | title = Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders | journal = Drugs | volume = 70 | issue = 3 | pages = 287–312 | date = February 2010 | pmid = 20166767 | doi = 10.2165/11319230-000000000-00000 | s2cid = 12176745 }}</ref>


In the United States, [[dietary supplement]]s may be marketed if the manufacturer can show that the supplement is [[generally recognized as safe]], and if the manufacturer does not make any claims about using the supplement to treat or prevent any disease or condition; supplements that contain drugs or advertise [[health claim]]s are illegal under US law.<ref>{{cite journal | vauthors = Goldman P | title = Herbal medicines today and the roots of modern pharmacology | journal = Annals of Internal Medicine | volume = 135 | issue = 8 Pt 1 | pages = 594–600 | date = October 2001 | pmid = 11601931 | doi = 10.7326/0003-4819-135-8_Part_1-200110160-00010 | s2cid = 35766876 }}</ref>
In the United States, dietary supplements may be marketed if the manufacturer can show that the supplement is [[generally recognized as safe]], and if the manufacturer does not make any claims about using the supplement to treat or prevent any disease or condition; supplements that contain drugs or advertise [[health claim]]s are illegal under US law.<ref>{{cite journal | vauthors = Goldman P | title = Herbal medicines today and the roots of modern pharmacology | journal = Annals of Internal Medicine | volume = 135 | issue = 8 Pt 1 | pages = 594–600 | date = October 2001 | pmid = 11601931 | doi = 10.7326/0003-4819-135-8_Part_1-200110160-00010 | s2cid = 35766876 }}</ref>


==Types==
==Types==
Line 55: Line 57:


=== Central nervous system stimulants {{anchor|Xanthines|Stimulants}} ===
=== Central nervous system stimulants {{anchor|Xanthines|Stimulants}} ===
[[Systematic review]]s and [[meta-analyses]] of [[clinical research]] using low doses of certain [[central nervous system]] stimulants found that these drugs may enhance cognition in healthy people.<ref name="Unambiguous PFC D1 A2" /><ref name="Cognitive and motivational effects">{{cite journal | vauthors = Ilieva IP, Hook CJ, Farah MJ | title = Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis | journal = Journal of Cognitive Neuroscience | volume = 27 | issue = 6 | pages = 1069–1089 | date = June 2015 | pmid = 25591060 | doi = 10.1162/jocn_a_00776 | s2cid = 15788121 | url = https://repository.upenn.edu/neuroethics_pubs/130 }}</ref><ref name="Systematic 2014 – Amph, MPH, Modafinil">{{cite journal | vauthors = Bagot KS, Kaminer Y | title = Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review | journal = Addiction | volume = 109 | issue = 4 | pages = 547–557 | date = April 2014 | pmid = 24749160 | pmc = 4471173 | doi = 10.1111/add.12460 }}</ref> In particular, the classes of stimulants that demonstrate possible cognition-enhancing effects in humans have evidence [[in vitro]] as [[receptor agonist|direct agonists]] or [[indirect agonist]]s of [[dopamine receptor D1|dopamine receptor D<sub>1</sub>]] or [[Alpha-2 adrenergic receptor|adrenoceptor A<sub>2</sub>]].<ref name="Unambiguous PFC D1 A2">{{cite journal | vauthors = Spencer RC, Devilbiss DM, Berridge CW | title = The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex | journal = Biological Psychiatry | volume = 77 | issue = 11 | pages = 940–950 | date = June 2015 | pmid = 25499957 | pmc = 4377121 | doi = 10.1016/j.biopsych.2014.09.013 }}</ref><ref name="Cognitive and motivational effects" /><ref name="Continuum">{{cite journal | vauthors = Wood S, Sage JR, Shuman T, Anagnostaras SG | title = Psychostimulants and cognition: a continuum of behavioral and cognitive activation | journal = Pharmacological Reviews | volume = 66 | issue = 1 | pages = 193–221 | date = January 2014 | pmid = 24344115 | pmc = 3880463 | doi = 10.1124/pr.112.007054 }}</ref><ref name="NHMH_3e-Higher Cognitive Function">{{cite book | vauthors = Malenka RC, Nestler EJ, Hyman SE, Holtzman DM | title = Molecular Neuropharmacology: A Foundation for Clinical Neuroscience | year = 2015 | publisher = McGraw-Hill Medical | location = New York | isbn = 9780071827706 | edition = 3| chapter = 14: Higher Cognitive Function and Behavioral Control}}</ref> Relatively high doses of stimulants cause cognitive deficits.<ref name="Continuum" /><ref name="NHMH_3e-Higher Cognitive Function" />
{{See also|Yerkes–Dodson law|Stimulant}}
* [[Amphetamine]]{{snd}} systematic reviews and meta-analyses report that low-dose amphetamine may improve cognitive functions (e.g., [[inhibitory control]], [[episodic memory]], [[working memory]], and aspects of [[Attention#Clinical model|attention]]) in healthy people and in individuals with ADHD.<ref name="Unambiguous PFC D1 A2" /><ref name="Cognitive and motivational effects" /><ref name="Systematic 2014 – Amph, MPH, Modafinil" /><ref name="NHMH_3e-Higher Cognitive Function" /> A 2014 systematic review noted that low doses of amphetamine also improve [[memory consolidation]], in turn leading to improved [[Recall (memory)|recall of information]] in non-ADHD youth.<ref name="Systematic 2014 – Amph, MPH, Modafinil" /> It also improves [[incentive salience|task saliency]] (motivation to perform a task) and performance on tedious tasks that required a high degree of effort.<ref name="Cognitive and motivational effects" /><ref name="Continuum" /><ref name="NHMH_3e-Higher Cognitive Function" />
[[Image:HebbianYerkesDodson.svg|thumb|right|Hebbian version of the [[Yerkes–Dodson law]] ]]
[[Systematic review]]s and [[meta-analyses]] of [[clinical research|clinical human research]] using low doses of certain [[central nervous system]] [[stimulant]]s found that these drugs enhance cognition in healthy people.<ref name="Unambiguous PFC D1 A2" /><ref name="Cognitive and motivational effects">{{cite journal | vauthors = Ilieva IP, Hook CJ, Farah MJ | title = Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis | journal = Journal of Cognitive Neuroscience | volume = 27 | issue = 6 | pages = 1069–1089 | date = June 2015 | pmid = 25591060 | doi = 10.1162/jocn_a_00776 | s2cid = 15788121 | url = https://repository.upenn.edu/neuroethics_pubs/130 }}</ref><ref name="Systematic 2014 – Amph, MPH, Modafinil">{{cite journal | vauthors = Bagot KS, Kaminer Y | title = Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review | journal = Addiction | volume = 109 | issue = 4 | pages = 547–557 | date = April 2014 | pmid = 24749160 | pmc = 4471173 | doi = 10.1111/add.12460 }}</ref> In particular, the classes of stimulants that demonstrate cognition-enhancing effects in humans act as [[receptor agonist|direct agonists]] or [[indirect agonist]]s of [[dopamine receptor D1|dopamine receptor D<sub>1</sub>]], [[Alpha-2 adrenergic receptor|adrenoceptor A<sub>2</sub>]], or both receptors in the [[prefrontal cortex]].<ref name="Unambiguous PFC D1 A2">{{cite journal | vauthors = Spencer RC, Devilbiss DM, Berridge CW | title = The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex | journal = Biological Psychiatry | volume = 77 | issue = 11 | pages = 940–950 | date = June 2015 | pmid = 25499957 | pmc = 4377121 | doi = 10.1016/j.biopsych.2014.09.013 }}</ref><ref name="Cognitive and motivational effects" /><ref name="Continuum">{{cite journal | vauthors = Wood S, Sage JR, Shuman T, Anagnostaras SG | title = Psychostimulants and cognition: a continuum of behavioral and cognitive activation | journal = Pharmacological Reviews | volume = 66 | issue = 1 | pages = 193–221 | date = January 2014 | pmid = 24344115 | pmc = 3880463 | doi = 10.1124/pr.112.007054 }}</ref><ref name="NHMH_3e-Higher Cognitive Function">{{cite book | vauthors = Malenka RC, Nestler EJ, Hyman SE, Holtzman DM | title = Molecular Neuropharmacology: A Foundation for Clinical Neuroscience | year = 2015 | publisher = McGraw-Hill Medical | location = New York | isbn = 9780071827706 | edition = 3| chapter = 14: Higher Cognitive Function and Behavioral Control}}</ref> Relatively high doses of stimulants cause cognitive deficits.<ref name="Continuum" /><ref name="NHMH_3e-Higher Cognitive Function" />
* [[Amphetamine]]{{snd}} systematic reviews and meta-analyses report that low-dose amphetamine improves cognitive functions (e.g., [[inhibitory control]], [[episodic memory]], [[working memory]], and aspects of [[Attention#Clinical model|attention]]) in healthy people and in individuals with ADHD.<ref name="Unambiguous PFC D1 A2" /><ref name="Cognitive and motivational effects" /><ref name="Systematic 2014 – Amph, MPH, Modafinil" /><ref name="NHMH_3e-Higher Cognitive Function" /> A 2014 systematic review noted that low doses of amphetamine also improve [[memory consolidation]], in turn leading to improved [[Recall (memory)|recall of information]] in non-ADHD youth.<ref name="Systematic 2014 – Amph, MPH, Modafinil" /> It also improves [[incentive salience|task saliency]] (motivation to perform a task) and performance on tedious tasks that required a high degree of effort.<ref name="Cognitive and motivational effects" /><ref name="Continuum" /><ref name="NHMH_3e-Higher Cognitive Function" />
* [[Caffeine]]{{snd}} a meta-analysis found an increase in alertness and attentional performance.<ref name="caffeine and theanine">{{cite journal | vauthors = Camfield DA, Stough C, Farrimond J, Scholey AB | title = Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis | journal = Nutrition Reviews | volume = 72 | issue = 8 | pages = 507–522 | date = August 2014 | pmid = 24946991 | doi = 10.1111/nure.12120 | doi-access = free }}</ref><ref name="Continuum" />
* [[Caffeine]]{{snd}} a meta-analysis found an increase in alertness and attentional performance.<ref name="caffeine and theanine">{{cite journal | vauthors = Camfield DA, Stough C, Farrimond J, Scholey AB | title = Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis | journal = Nutrition Reviews | volume = 72 | issue = 8 | pages = 507–522 | date = August 2014 | pmid = 24946991 | doi = 10.1111/nure.12120 | doi-access = free }}</ref><ref name="Continuum" />
* [[Eugeroics]] ([[armodafinil]] and [[modafinil]]){{snd}} are classified as "wakefulness-promoting agents"; modafinil increases alertness, particularly in [[sleep-deprived]] individuals, and facilitates reasoning and problem solving in non-ADHD youth.<ref name="Systematic 2014 – Amph, MPH, Modafinil" /> In a systematic review of small, preliminary studies where the effects of modafinil were examined, when simple psychometric assessments were considered, modafinil intake enhanced executive function.<ref name="Modafinil SystRev">{{cite journal | vauthors = Battleday RM, Brem AK | title = Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review | journal = European Neuropsychopharmacology | volume = 25 | issue = 11 | pages = 1865–1881 | date = November 2015 | pmid = 26381811 | doi = 10.1016/j.euroneuro.2015.07.028 | s2cid = 23319688 }}</ref> Modafinil may not produce improvements in mood or motivation in sleep deprived or non-sleep deprived individuals.<ref>{{cite book | vauthors = Mohamed AD | chapter = Does modafinil improve cognitive functioning in healthy individuals? | veditors = ter Meulen R, Hall W, Mohammed AD | name-list-style = vanc |title=Rethinking Cognitive Enhancement |date=2017 |publisher=Oxford University Press |isbn=9780198727392 |page=116 | chapter-url=https://books.google.com/books?id=aAIXDgAAQBAJ&pg=PA116 }}</ref>
* [[Eugeroics]] ([[armodafinil]] and [[modafinil]]){{snd}} are classified as "wakefulness-promoting agents"; modafinil may increase alertness, particularly in [[sleep-deprived]] individuals, and may improve reasoning and problem solving in non-ADHD youth.<ref name="Systematic 2014 – Amph, MPH, Modafinil" /> In a systematic review of small, preliminary studies where the effects of modafinil were examined, when simple psychometric assessments were considered, modafinil intake enhanced executive function.<ref name="Modafinil SystRev">{{cite journal | vauthors = Battleday RM, Brem AK | title = Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review | journal = European Neuropsychopharmacology | volume = 25 | issue = 11 | pages = 1865–1881 | date = November 2015 | pmid = 26381811 | doi = 10.1016/j.euroneuro.2015.07.028 | s2cid = 23319688 }}</ref> Modafinil does not improve mood or motivation in sleep-deprived or non-sleep deprived individuals.<ref>{{cite book | vauthors = Mohamed AD | chapter = Does modafinil improve cognitive functioning in healthy individuals? | veditors = ter Meulen R, Hall W, Mohammed AD |title=Rethinking Cognitive Enhancement |date=2017 |publisher=Oxford University Press |isbn=9780198727392 |page=116 | chapter-url=https://books.google.com/books?id=aAIXDgAAQBAJ&pg=PA116 }}</ref>
* [[Methylphenidate]]{{snd}} a [[benzylpiperidine]] derivative that improves [[working memory]], [[episodic memory]], and [[inhibitory control]], aspects of [[Attention#Clinical model|attention]], and planning latency in healthy people.<ref name="Unambiguous PFC D1 A2" /><ref name="Cognitive and motivational effects" /><ref name="Systematic 2014 – Amph, MPH, Modafinil" /> It also may improve task saliency and performance on tedious tasks.<ref name="NHMH_3e-Higher Cognitive Function" /> At above optimal doses, methylphenidate has off–target effects that decrease learning.<ref>{{cite journal | vauthors = Urban KR, Gao WJ | title = Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brain | journal = Frontiers in Systems Neuroscience | volume = 8 | pages = 38 | date = 2014 | pmid = 24860437 | pmc = 4026746 | doi = 10.3389/fnsys.2014.00038 | doi-access = free }}</ref>
* [[Methylphenidate]]{{snd}} a [[benzylpiperidine]] derivative that may improve [[working memory]], [[episodic memory]], and [[inhibitory control]], aspects of [[Attention#Clinical model|attention]], and planning latency in healthy people.<ref name="Unambiguous PFC D1 A2" /><ref name="Systematic 2014 – Amph, MPH, Modafinil" /> It also may improve task saliency and performance on tedious tasks.<ref name="NHMH_3e-Higher Cognitive Function" /> At above optimal doses, methylphenidate has off–target effects that decrease learning.<ref>{{cite journal | vauthors = Urban KR, Gao WJ | title = Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brain | journal = Frontiers in Systems Neuroscience | volume = 8 | pages = 38 | date = 2014 | pmid = 24860437 | pmc = 4026746 | doi = 10.3389/fnsys.2014.00038 | doi-access = free }}</ref>
* [[Nicotine]]{{snd}} a meta-analysis of 41 clinical studies concluded that [[nicotine]] administration or smoking improves alerting and orienting attention and episodic and working memory and slightly improves fine motor performance.<ref>{{cite journal | vauthors = Heishman SJ, Kleykamp BA, Singleton EG | title = Meta-analysis of the acute effects of nicotine and smoking on human performance | journal = Psychopharmacology | volume = 210 | issue = 4 | pages = 453–469 | date = July 2010 | pmid = 20414766 | pmc = 3151730 | doi = 10.1007/s00213-010-1848-1 }}</ref>
* [[Nicotine]]{{snd}} has been associated with improved alertness, attention, memory, and motor performance, according to a [[meta-analysis]].<ref>{{cite journal | vauthors = Heishman SJ, Kleykamp BA, Singleton EG | title = Meta-analysis of the acute effects of nicotine and smoking on human performance | journal = Psychopharmacology | volume = 210 | issue = 4 | pages = 453–469 | date = July 2010 | pmid = 20414766 | pmc = 3151730 | doi = 10.1007/s00213-010-1848-1 }}</ref> However, a 2020 systematic review raised concerns about potential conflicts of interest, noting industry funding in many studies and inconsistent results regarding nicotine's cognitive effects. This review found that over half of the studies published after 2010 had tobacco industry affiliations, often undisclosed.<ref name="pmid32547048">{{cite journal |last1=Pasetes |first1=Sarah V. |last2=Ling |first2=Pamela M. |last3=Apollonio |first3=Dorie E. |title=Cognitive performance effects of nicotine and industry affiliation: a systematic review |journal=Substance Abuse: Research and Treatment |date=January 2020 |volume=14 |pages=117822182092654 |doi=10.1177/1178221820926545 |pmid=32547048 |language=en |issn=1178-2218 |pmc=7271274}}</ref>

===Amino acids===
{{Main|Amino acid-based formula}}

A 2016 review reported that [[theanine]] may increase [[alpha wave]]s in the brain. Alpha waves may contribute to a relaxed yet alert mental state.<ref>{{cite journal | vauthors = Borchers A, Pieler T | title = Programming pluripotent precursor cells derived from Xenopus embryos to generate specific tissues and organs | journal = Genes | volume = 1 | issue = 3 | pages = 413–426 | date = November 2010 | pmid = 24710095 | doi = 10.3390/beverages2020013 | pmc = 3966229 | doi-access = free }}</ref> A 2014 systematic review and meta-analysis found that concurrent caffeine and {{smallcaps all|L}}-theanine use had [[synergy#Drug synergy|synergistic]] psychoactive effects that promoted alertness, attention, and [[Task switching (psychology)|task switching]]. These effects were most pronounced during the first hour post-dose.<ref name="caffeine and theanine" />


===Racetams===
===Racetams===
{{Main|Racetam}}
{{Main|Racetam}}
Racetams, such as piracetam, [[oxiracetam]], [[phenylpiracetam]], and [[aniracetam]], are often marketed as cognitive enhancers and sold [[over the counter]].<ref name="NeuroClin">{{cite journal | vauthors = Cohen PA, Avula B, Wang YH, Zakharevich I, Khan I | title = Five Unapproved Drugs Found in Cognitive Enhancement Supplements | journal = Neurology. Clinical Practice | volume = 11 | issue = 3 | pages = e303–e307 | date = June 2021 | pmid = 34484905 | pmc = 8382366 | doi = 10.1212/CPJ.0000000000000960 }}</ref><ref name="JAMAIM">{{cite journal | vauthors = Cohen PA, Zakharevich I, Gerona R | title = Presence of Piracetam in Cognitive Enhancement Dietary Supplements | journal = JAMA Internal Medicine | volume = 180 | issue = 3 | pages = 458–459 | date = March 2020 | pmid = 31764936 | pmc = 6902196 | doi = 10.1001/jamainternmed.2019.5507 }}</ref> A 2019 study found that piracetam supplements sold in the United States were inaccurately labeled.<ref name="JAMAIM"/> Racetams are often referred to as nootropics, but this property is not well established.<ref name="NHM">{{cite book |vauthors=Malenka RC, Nestler EJ, Hyman SE |veditors=Sydor A, Brown RY | title = Molecular Neuropharmacology: A Foundation for Clinical Neuroscience | year = 2009 | publisher = McGraw-Hill Medical | location = New York | isbn = 9780071481274 | page = 454 | edition = 2 }}</ref> The racetams have poorly understood [[mechanism of action|mechanisms]], although piracetam and aniracetam are known to act as [[positive allosteric modulator]]s of [[AMPA receptor]]s and appear to modulate [[acetylcholine|cholinergic]] systems.<ref>{{cite journal | vauthors = Gualtieri F, Manetti D, Romanelli MN, Ghelardini C | title = Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs | journal = Current Pharmaceutical Design | volume = 8 | issue = 2 | pages = 125–138 | year = 2002 | pmid = 11812254 | doi = 10.2174/1381612023396582 }}</ref>
Racetams, such as piracetam, [[oxiracetam]], [[phenylpiracetam]], and [[aniracetam]], are often marketed as cognitive enhancers and sold [[over the counter]].<ref name="NeuroClin">{{cite journal | vauthors = Cohen PA, Avula B, Wang YH, Zakharevich I, Khan I | title = Five Unapproved Drugs Found in Cognitive Enhancement Supplements | journal = Neurology. Clinical Practice | volume = 11 | issue = 3 | pages = e303–e307 | date = June 2021 | pmid = 34484905 | pmc = 8382366 | doi = 10.1212/CPJ.0000000000000960 }}</ref><ref name="JAMAIM">{{cite journal | vauthors = Cohen PA, Zakharevich I, Gerona R | title = Presence of Piracetam in Cognitive Enhancement Dietary Supplements | journal = JAMA Internal Medicine | volume = 180 | issue = 3 | pages = 458–459 | date = March 2020 | pmid = 31764936 | pmc = 6902196 | doi = 10.1001/jamainternmed.2019.5507 }}</ref> A 2019 study found that piracetam supplements sold in the United States were inaccurately labeled.<ref name="JAMAIM"/> Racetams are often referred to as nootropics, but this property is not well established in humans, and nootropics are not consistently found in all racetams.<ref name="NHM">{{cite book |vauthors=Malenka RC, Nestler EJ, Hyman SE |veditors=Sydor A, Brown RY | title = Molecular Neuropharmacology: A Foundation for Clinical Neuroscience | year = 2009 | publisher = McGraw-Hill Medical | location = New York | isbn = 9780071481274 | page = 454 | edition = 2 }}</ref> The racetams have poorly understood [[mechanism of action|mechanisms]], although piracetam and aniracetam are known to act as [[positive allosteric modulator]]s of [[AMPA receptor]]s and appear to modulate [[acetylcholine|cholinergic]] systems.<ref>{{cite journal | vauthors = Gualtieri F, Manetti D, Romanelli MN, Ghelardini C | title = Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs | journal = Current Pharmaceutical Design | volume = 8 | issue = 2 | pages = 125–138 | year = 2002 | pmid = 11812254 | doi = 10.2174/1381612023396582 }}</ref>


According to the FDA,
According to the FDA,


<blockquote>Piracetam is not a [[vitamin]], mineral, [[amino acid]], herb or other [[botanical]], or dietary substance for use by humans to supplement the diet by increasing the total dietary intake. Further, piracetam is not a concentrate, metabolite, constituent, extract or combination of any such dietary ingredient. [...] Accordingly, these products are drugs, under section 201(g)(1)(C) of the Act, 21 U.S.C. § 321(g)(1)(C), because they are not foods and they are intended to affect the structure or any function of the body. Moreover, these products are new drugs as defined by section 201(p) of the Act, 21 U.S.C. § 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling.<ref name="unlimited">{{Cite web|url=https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2010/ucm225605.htm|archive-url=https://wayback.archive-it.org/7993/20170112004501/https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2010/ucm225605.htm|url-status=dead|archive-date=12 January 2017|title=FDA Warning Letter: Unlimited Nutrition|author=John Gridley|date=30 August 2010|publisher=Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration |access-date=5 April 2016}}</ref></blockquote>
<blockquote>Piracetam is not a [[vitamin]], mineral, [[amino acid]], herb or other [[botanical]], or dietary substance for use by humans to supplement the diet by increasing the total dietary intake. Further, piracetam is not a concentrate, metabolite, constituent, extract or combination of any such dietary ingredient. [...] Accordingly, these products are drugs, under section 201(g)(1)(C) of the Act, 21 U.S.C. § 321(g)(1)(C), because they are not foods and they are intended to affect the structure or any function of the body. Moreover, these products are new drugs as defined by section 201(p) of the Act, 21 U.S.C. § 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling.<ref name="unlimited">{{cite web|url=https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2010/ucm225605.htm|archive-url=https://wayback.archive-it.org/7993/20170112004501/https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2010/ucm225605.htm|url-status=dead|archive-date=12 January 2017|title=FDA Warning Letter: Unlimited Nutrition|author=John Gridley|date=30 August 2010|publisher=Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration |access-date=5 April 2016}}</ref></blockquote>


===Cholinergics===
===Cholinergics===
{{more medical citations needed|section|date=August 2020}}
{{Main|Cholinergic}}
{{Main|Cholinergic}}
Some of the most widely used nootropic substances are the cholinergics. These are typically compounds and analogues of [[choline]]. Choline is an essential nutrient needed for the synthesis of acetylcholine (a neurotransmitter), and phosphatidylcholine (a structural component of brain cell membranes).
Some supposed nootropic substances are compounds and analogues of [[choline]], a [[precursor (chemistry)|precursor]] of acetylcholine (a [[neurotransmitter]]) and [[phosphatidylcholine]] (a structural component of [[cell membrane]]s).
* [[Alpha-GPC]] – L-Alpha glycerylphosphorylcholine has thus far only been studied in the context of cognitive performance alongside other substances such as caffeine.<ref>{{Cite journal| vauthors = Parker AG, Byars A, Purpura M, Jäger R |date=September 21, 2015|title=The effects of alpha-glycerylphosphorylcholine, caffeine or placebo on markers of mood, cognitive function, power, speed, and agility|journal=Journal of the International Society of Sports Nutrition|volume=12|issue=Suppl 1|pages=P41|doi=10.1186/1550-2783-12-S1-P41|issn=1550-2783|pmc=4595381 |doi-access=free }}</ref> A more comprehensive meta-analysis is needed before any strong conclusions are made about Alpha-GPC's usefulness as a nootropic.
* [[Alpha-GPC]] – L-alpha glycerylphosphorylcholine has been studied only in the context of cognitive performance alongside other substances such as caffeine.<ref>{{cite journal| vauthors = Parker AG, Byars A, Purpura M, Jäger R |date=September 21, 2015|title=The effects of alpha-glycerylphosphorylcholine, caffeine or placebo on markers of mood, cognitive function, power, speed, and agility|journal=Journal of the International Society of Sports Nutrition|volume=12|issue=Suppl 1|pages=P41|doi=10.1186/1550-2783-12-S1-P41|issn=1550-2783|pmc=4595381 |doi-access=free }}</ref>
* [[Choline bitartrate]] – Choline bitartrate is a tartaric acid salt containing choline (41% choline by molecular weight). At least one meta-analysis has found choline bitartrate to be ineffective at improving any measure of cognitive performance.<ref>{{cite journal | vauthors = Lippelt DP, van der Kint S, van Herk K, Naber M | title = No Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults | journal = PLOS ONE | volume = 11 | issue = 6 | pages = e0157714 | date = June 24, 2016 | pmid = 27341028 | pmc = 4920398 | doi = 10.1371/journal.pone.0157714 | doi-access = free | bibcode = 2016PLoSO..1157714L }}</ref>
* [[Choline bitartrate]] – Choline bitartrate is a [[tartaric acid]] salt containing choline (41% choline by molecular weight). One meta-analysis found choline bitartrate to be ineffective at improving any measure of cognitive performance.<ref>{{cite journal | vauthors = Lippelt DP, van der Kint S, van Herk K, Naber M | title = No Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults | journal = PLOS ONE | volume = 11 | issue = 6 | pages = e0157714 | date = June 24, 2016 | pmid = 27341028 | pmc = 4920398 | doi = 10.1371/journal.pone.0157714 | doi-access = free | bibcode = 2016PLoSO..1157714L }}</ref>
* [[Citicoline]] – Compound consisting of choline and [[cytidine]]. Several meta-analyses found that it is likely effective for improving memory and learning in older people with mild cognitive decline, as well as in people who are recovering from a stroke.<ref>{{cite journal | vauthors = Fioravanti M, Buckley AE | title = Citicoline (Cognizin) in the treatment of cognitive impairment | journal = Clinical Interventions in Aging | volume = 1 | issue = 3 | pages = 247–251 | date = September 2006 | pmid = 18046877 | pmc = 2695184 | doi = 10.2147/ciia.2006.1.3.247 | doi-access = free }}</ref><ref>{{Cite web| vauthors = Tardner P |date=August 30, 2020|title=The use of citicoline for the treatment of cognitive decline and cognitive impairment: A meta-analysis of pharmacological literature |url=https://www.ijest.org/citicoline-cognitive-decline-ptardner-0820/|access-date=August 31, 2020|website=International Journal of Environmental Science & Technology|language=en-US}}</ref><ref>{{cite journal | vauthors = Franco-Maside A, Caamaño J, Gómez MJ, Cacabelos R | title = Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer's disease | journal = Methods and Findings in Experimental and Clinical Pharmacology | volume = 16 | issue = 8 | pages = 597–607 | date = October 1994 | pmid = 7760585 }}</ref> There is little evidence it enhances cognition in young, healthy people.
* [[Citicoline]] – Compound consisting of choline and [[cytidine]]. A meta-analysis found that it may be effective for improving memory and learning in older people with mild cognitive decline, and in people recovering from a stroke.<ref>{{cite journal | vauthors = Fioravanti M, Buckley AE | title = Citicoline (Cognizin) in the treatment of cognitive impairment | journal = Clinical Interventions in Aging | volume = 1 | issue = 3 | pages = 247–251 | date = September 2006 | pmid = 18046877 | pmc = 2695184 | doi = 10.2147/ciia.2006.1.3.247 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Franco-Maside A, Caamaño J, Gómez MJ, Cacabelos R | title = Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer's disease | journal = Methods and Findings in Experimental and Clinical Pharmacology | volume = 16 | issue = 8 | pages = 597–607 | date = October 1994 | pmid = 7760585 }}</ref>
* [[Cyprodenate]]
* [[Meclofenoxate]]

===Miscellaneous===
* [[Atomoxetine]]{{snd}} may improve [[working memory]] and attention when used at certain doses.<ref name="NHMH_3e-Higher Cognitive Function" />
* [[Desipramine]]{{snd}} may improve [[working memory]] and attention when used at certain doses.<ref name="NHMH_3e-Higher Cognitive Function" />
* [[ISRIB]] enhanced spatial and fear-associated learning.<ref>{{cite journal | vauthors = Sidrauski C, Acosta-Alvear D, Khoutorsky A, Vedantham P, Hearn BR, Li H, Gamache K, Gallagher CM, Ang KK, Wilson C, Okreglak V, Ashkenazi A, Hann B, Nader K, Arkin MR, Renslo AR, Sonenberg N, Walter P | display-authors = 6 | title = Pharmacological brake-release of mRNA translation enhances cognitive memory | journal = eLife | volume = 2 | pages = e00498 | date = May 2013 | pmid = 23741617 | pmc = 3667625 | doi = 10.7554/eLife.00498 | doi-access = free }}</ref>
* [[Levodopa]]{{snd}} a systematic review noted that it improved verbal episodic memory and episodic memory encoding.<ref name="Nootropic pharmacodynamics systematic review" /> and is sold as ''M pruriens'' dietary supplements in the US.<ref>{{cite journal | vauthors = Cohen PA, Avula B, Katragunta K, Khan I | title = Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database | journal = JAMA Neurology | volume = 79 | issue = 10 | pages = 1085–1086 | date = October 2022 | pmid = 35939305 | pmc = 9361182 | doi = 10.1001/jamaneurol.2022.2184 }}</ref>
* [[Nicergoline]] may improve human cognitive performance, including concentration, psychomotor performance, attention, reaction times, and other indicators of brain function.<ref name="myths">{{cite journal | vauthors = Zajdel P, Bednarski M, Sapa J, Nowak G | title = Ergotamine and nicergoline - facts and myths | journal = Pharmacological Reports | volume = 67 | issue = 2 | pages = 360–363 | date = April 2015 | pmid = 25712664 | doi = 10.1016/j.pharep.2014.10.010 | s2cid = 22768662 }}</ref>
* [[Tolcapone]]{{snd}} a systematic review noted that it improved verbal [[episodic memory]] and episodic [[memory encoding]].<ref name="Nootropic pharmacodynamics systematic review">{{cite journal | vauthors = Fond G, Micoulaud-Franchi JA, Brunel L, Macgregor A, Miot S, Lopez R, Richieri R, Abbar M, Lancon C, Repantis D | display-authors = 6 | title = Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review | journal = Psychiatry Research | volume = 229 | issue = 1–2 | pages = 12–20 | date = September 2015 | pmid = 26187342 | doi = 10.1016/j.psychres.2015.07.006 | s2cid = 23647057 }}</ref>

The cognitive enhancing effects of [[pramipexole]], [[guanfacine]], [[clonidine]], and [[fexofenadine]] have been tested, but no significant cognition-enhancing effects in healthy individuals were found.<ref name="Nootropic pharmacodynamics systematic review" />

[[Psychedelic microdosing]] is the novel practice of using sub-threshold doses (microdoses) of [[psychedelic drugs]] in an attempt to improve mood and cognition.<ref name="psychedelic1">{{Cite journal| vauthors = Fadiman J |date=January 1, 2016|title=Microdose research: without approvals, control groups, double blinds, staff or funding|url=https://www.researchgate.net/publication/308138461|journal=Psychedelic Press|volume=XV}}</ref> The efficacy of this has not been verified.<ref name=":psychedelic2">{{cite journal | vauthors = Webb M, Copes H, Hendricks PS | title = Narrative identity, rationality, and microdosing classic psychedelics | journal = The International Journal on Drug Policy | volume = 70 | pages = 33–39 | date = August 2019 | pmid = 31071597 | doi = 10.1016/j.drugpo.2019.04.013 | s2cid = 149445841 }}</ref><ref name=":psychedelic3">{{cite journal | vauthors = Polito V, Stevenson RJ | title = A systematic study of microdosing psychedelics | journal = PLOS ONE | volume = 14 | issue = 2 | pages = e0211023 | date = February 6, 2019 | pmid = 30726251 | pmc = 6364961 | doi = 10.1371/journal.pone.0211023 | doi-access = free | bibcode = 2019PLoSO..1411023P }}</ref> In a study examining the qualitative reports of 278 microdosers the researchers found that there were mixed results among users.<ref name=":psychedelic4">{{cite journal | vauthors = Anderson T, Petranker R, Christopher A, Rosenbaum D, Weissman C, Dinh-Williams LA, Hui K, Hapke E | display-authors = 6 | title = Psychedelic microdosing benefits and challenges: an empirical codebook | journal = Harm Reduction Journal | volume = 16 | issue = 1 | pages = 43 | date = July 2019 | pmid = 31288862 | pmc = 6617883 | doi = 10.1186/s12954-019-0308-4 | doi-access = free }}</ref> While some users reported positive effects such as improved mood and cognition, others [[paradoxical reaction|paradoxically]] reported negative effects such as physiological discomfort and [[anxiety]].<ref name=":psychedelic4" /> In one of the only double-blind, randomized studies to date, those given microdoses of [[LSD]] did not perform better than those given the placebo on cognitive tasks.<ref name="psychedelic5">{{cite journal | vauthors = Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H | title = Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers | journal = Biological Psychiatry | volume = 86 | issue = 10 | pages = 792–800 | date = November 2019 | pmid = 31331617 | pmc = 6814527 | doi = 10.1016/j.biopsych.2019.05.019 }}</ref>


==Herbs==
==Herbs==
* ''[[Centella asiatica]]''{{snd}} A 2017 meta-analysis showed no significant improvement in cognitive function.<ref name="pmid28878245">{{cite journal | vauthors = Puttarak P, Dilokthornsakul P, Saokaew S, Dhippayom T, Kongkaew C, Sruamsiri R, Chuthaputti A, Chaiyakunapruk N | title = Effects of Centella asiatica (L.) Urb. on cognitive function and mood related outcomes: A Systematic Review and Meta-analysis | journal = Scientific Reports | volume = 7 | issue = 1 | pages = 10646 | date = September 2017 | pmid = 28878245 | pmc = 5587720 | doi = 10.1038/s41598-017-09823-9 | bibcode = 2017NatSR...710646P }}</ref> Clinical efficacy and safety have not been scientifically confirmed for this herb.<ref name="drugs">{{cite web|title=Gotu kola|url=https://www.drugs.com/npp/gotu-kola.html|publisher=Drugs.com|access-date=21 September 2023|date=23 January 2023}}</ref>
* ''[[Bacopa monnieri]]'' is used in [[Ayurveda|Ayurvedic traditional medicine]] to improve cognition.<ref name=Aguiar2013>{{cite journal | vauthors = Aguiar S, Borowski T | title = Neuropharmacological review of the nootropic herb Bacopa monnieri | journal = Rejuvenation Research | volume = 16 | issue = 4 | pages = 313–326 | date = August 2013 | pmid = 23772955 | pmc = 3746283 | doi = 10.1089/rej.2013.1431 }}</ref> [[Systematic review]]s of preliminary research found that ''Bacopa monnieri'' may improve cognition, specifically memory and learning,<ref name=Aguiar2013/><ref name=Konkeaw2014>{{cite journal | vauthors = Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, Limpeanchob N, Norman Scholfield C | title = Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract | journal = Journal of Ethnopharmacology | volume = 151 | issue = 1 | pages = 528–535 | date = 2014 | pmid = 24252493 | doi = 10.1016/j.jep.2013.11.008 }}</ref> although the effect was measurable only after more than 12 weeks of use.<ref name="Neale">{{cite journal | vauthors = Neale C, Camfield D, Reay J, Stough C, Scholey A | title = Cognitive effects of two nutraceuticals Ginseng and Bacopa benchmarked against modafinil: a review and comparison of effect sizes | journal = British Journal of Clinical Pharmacology | volume = 75 | issue = 3 | pages = 728–737 | date = March 2013 | pmid = 23043278 | pmc = 3575939 | doi = 10.1111/bcp.12002 }}</ref>
* ''[[Centella asiatica]]''{{snd}} A 2017 meta-analysis showed no significant improvement in cognitive function.<ref name="pmid28878245">{{cite journal | vauthors = Puttarak P, Dilokthornsakul P, Saokaew S, Dhippayom T, Kongkaew C, Sruamsiri R, Chuthaputti A, Chaiyakunapruk N | display-authors = 6 | title = Effects of Centella asiatica (L.) Urb. on cognitive function and mood related outcomes: A Systematic Review and Meta-analysis | journal = Scientific Reports | volume = 7 | issue = 1 | pages = 10646 | date = September 2017 | pmid = 28878245 | pmc = 5587720 | doi = 10.1038/s41598-017-09823-9 | bibcode = 2017NatSR...710646P }}</ref> Clinical efficacy and safety have not been scientifically confirmed for this herb.<ref name="drugs">{{cite web|title=Gotu kola|url=https://www.drugs.com/npp/gotu-kola.html|publisher=Drugs.com|access-date=21 September 2023|date=23 January 2023}}</ref>
* ''[[Ginkgo biloba]]''{{snd}} An extract of ''Ginkgo biloba'' leaf is marketed in [[dietary supplement]] form with claims it can enhance [[cognitive function]] in people without known cognitive problems, although there is no high-quality evidence to support such effects on memory or attention in healthy people.<ref>{{cite journal | vauthors = Laws KR, Sweetnam H, Kondel TK | title = Is Ginkgo biloba a cognitive enhancer in healthy individuals? A meta-analysis | journal = Human Psychopharmacology | volume = 27 | issue = 6 | pages = 527–533 | date = November 2012 | pmid = 23001963 | doi = 10.1002/hup.2259 | s2cid = 6307491 }}</ref><ref name="nccih">{{cite web|url=http://nccih.nih.gov/health/ginkgo/ataglance.htm|date=September 2016|title=Ginkgo|publisher=National Center for Complementary and Integrative Health, US National Institutes of Health|access-date=July 9, 2018}}</ref>
* ''[[Ginkgo biloba]]''{{snd}} An extract of ''Ginkgo biloba'' leaf is marketed in [[dietary supplement]] form with claims it can enhance [[cognitive function]] in people without known cognitive problems, although there is no high-quality evidence to support such effects on memory or attention in healthy people.<ref>{{cite journal | vauthors = Laws KR, Sweetnam H, Kondel TK | title = Is Ginkgo biloba a cognitive enhancer in healthy individuals? A meta-analysis | journal = Human Psychopharmacology | volume = 27 | issue = 6 | pages = 527–533 | date = November 2012 | pmid = 23001963 | doi = 10.1002/hup.2259 | s2cid = 6307491 }}</ref><ref name="nccih">{{cite web|url=http://nccih.nih.gov/health/ginkgo/ataglance.htm|date=September 2016|title=Ginkgo|publisher=National Center for Complementary and Integrative Health, US National Institutes of Health|access-date=July 9, 2018}}</ref>
* ''[[Panax ginseng]]''{{snd}} A review by the [[Cochrane Collaboration]] found that the results of its analysis "suggested improvement of some aspects of cognitive function, behavior and quality of life" but concluded that "there is a lack of convincing evidence to show a cognitive enhancing effect of ''Panax ginseng'' in healthy participants and no high quality evidence about its efficacy in patients with dementia."<ref>{{cite journal | vauthors = Geng J, Dong J, Ni H, Lee MS, Wu T, Jiang K, Wang G, Zhou AL, Malouf R | display-authors = 6 | title = Ginseng for cognition | journal = The Cochrane Database of Systematic Reviews | issue = 12 | pages = CD007769 | date = December 2010 | pmid = 21154383 | doi = 10.1002/14651858.CD007769.pub2 }}</ref>
* ''[[Panax ginseng]]''{{snd}} A [[Cochrane Collaboration|Cochrane review]] found possible "improvement of some aspects of cognitive function, behavior and quality of life", but concluded that "there is a lack of convincing evidence to show a cognitive enhancing effect of ''Panax ginseng'' in healthy participants and no high quality evidence about its efficacy in patients with dementia."<ref>{{cite journal | vauthors = Geng J, Dong J, Ni H, Lee MS, Wu T, Jiang K, Wang G, Zhou AL, Malouf R | title = Ginseng for cognition | journal = The Cochrane Database of Systematic Reviews | issue = 12 | pages = CD007769 | date = December 2010 | pmid = 21154383 | doi = 10.1002/14651858.CD007769.pub2 }}</ref>
* ''[[Salvia officinalis]] and [[Salvia lavandulaefolia|lavandulaefolia]]'' (sage){{snd}} Some research has suggested certain extracts of ''Salvia officinalis'' may have positive effects on human brain function, but due to significant [[methodological]] problems, no firm conclusions can be drawn.<ref>{{cite journal | vauthors = Miroddi M, Navarra M, Quattropani MC, Calapai F, Gangemi S, Calapai G | title = Systematic review of clinical trials assessing pharmacological properties of Salvia species on memory, cognitive impairment and Alzheimer's disease | journal = CNS Neuroscience & Therapeutics | volume = 20 | issue = 6 | pages = 485–495 | date = June 2014 | pmid = 24836739 | pmc = 6493168 | doi = 10.1111/cns.12270 }}</ref><ref name=lopresti>{{cite journal | vauthors = Lopresti AL | title = Salvia (Sage): A Review of its Potential Cognitive-Enhancing and Protective Effects | journal = Drugs in R&D | volume = 17 | issue = 1 | pages = 53–64 | date = March 2017 | pmid = 27888449 | pmc = 5318325 | doi = 10.1007/s40268-016-0157-5 }}</ref> The [[thujone]] present in ''Salvia'' extracts may be [[neurotoxic]].<ref name=lopresti/>


==Nutrients and dietary supplements==
==Nutrients and dietary supplements==


* [[Folate]]{{snd}} no cognition-enhancing effects in [[middle-aged]] and older adults without folate deficiency.<ref name="Systematic rev – B vitamins">{{cite journal | vauthors = Forbes SC, Holroyd-Leduc JM, Poulin MJ, Hogan DB | title = Effect of Nutrients, Dietary Supplements and Vitamins on Cognition: a Systematic Review and Meta-Analysis of Randomized Controlled Trials | journal = Canadian Geriatrics Journal | volume = 18 | issue = 4 | pages = 231–245 | date = December 2015 | pmid = 26740832 | pmc = 4696451 | doi = 10.5770/cgj.18.189 }}</ref>
* [[Folate]]{{snd}} no cognition-enhancing effects in [[middle-aged]] and older adults without folate deficiency.<ref name="Systematic rev – B vitamins">{{cite journal | vauthors = Forbes SC, Holroyd-Leduc JM, Poulin MJ, Hogan DB | title = Effect of Nutrients, Dietary Supplements and Vitamins on Cognition: a Systematic Review and Meta-Analysis of Randomized Controlled Trials | journal = Canadian Geriatrics Journal | volume = 18 | issue = 4 | pages = 231–245 | date = December 2015 | pmid = 26740832 | pmc = 4696451 | doi = 10.5770/cgj.18.189 }}</ref>
* Omega-3 fatty acids: [[docosahexaenoic acid|DHA]] and [[eicosapentaenoic acid|EPA]]{{snd}} two [[Cochrane Collaboration]] reviews on the use of supplemental omega-3 fatty acids for ADHD and learning disorders conclude that there is limited evidence of treatment benefits for either disorder.<ref>{{cite journal | vauthors = Gillies D, Leach MJ, Perez Algorta G | title = Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents | journal = The Cochrane Database of Systematic Reviews | volume = 2023 | issue = 4 | pages = CD007986 | date = April 2023 | pmid = 37058600 | pmc = 10103546 | doi = 10.1002/14651858.CD007986.pub3 | pmc-embargo-date = April 14, 2024 }}</ref><ref name="Cochrane LD">{{cite journal | vauthors = Tan ML, Ho JJ, Teh KH | title = Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders | journal = The Cochrane Database of Systematic Reviews | volume = 12 | pages = CD009398 | date = December 2012 | pmid = 23235675 | doi = 10.1002/14651858.CD009398.pub2 | veditors = Tan ML }}</ref> Two other systematic reviews found no cognition-enhancing effects in the general population.<ref name="Systematic rev – B vitamins" /><ref name="Systematic review: Omega-3s">{{cite journal | vauthors = Cooper RE, Tye C, Kuntsi J, Vassos E, Asherson P | title = Omega-3 polyunsaturated fatty acid supplementation and cognition: A systematic review and meta-analysis | journal = Journal of Psychopharmacology | volume = 29 | issue = 7 | pages = 753–763 | date = July 2015 | pmid = 26040902 | doi = 10.1177/0269881115587958 | s2cid = 358375 }}</ref>
* Omega-3 fatty acids: [[docosahexaenoic acid|DHA]] and [[eicosapentaenoic acid|EPA]]{{snd}} two [[Cochrane Collaboration]] reviews on the use of supplemental omega-3 fatty acids for ADHD and learning disorders conclude that there is limited evidence of treatment benefits for either disorder.<ref>{{cite journal | vauthors = Gillies D, Leach MJ, Perez Algorta G | title = Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents | journal = The Cochrane Database of Systematic Reviews | volume = 2023 | issue = 4 | pages = CD007986 | date = April 2023 | pmid = 37058600 | pmc = 10103546 | doi = 10.1002/14651858.CD007986.pub3 }}</ref><ref name="Cochrane LD">{{cite journal | vauthors = Tan ML, Ho JJ, Teh KH | title = Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders | journal = The Cochrane Database of Systematic Reviews | volume = 12 | pages = CD009398 | date = December 2012 | pmid = 23235675 | doi = 10.1002/14651858.CD009398.pub2 | veditors = Tan ML }}</ref> Two other systematic reviews found no cognition-enhancing effects in the general population.<ref name="Systematic rev – B vitamins" /><ref name="Systematic review: Omega-3s">{{cite journal | vauthors = Cooper RE, Tye C, Kuntsi J, Vassos E, Asherson P | title = Omega-3 polyunsaturated fatty acid supplementation and cognition: A systematic review and meta-analysis | journal = Journal of Psychopharmacology | volume = 29 | issue = 7 | pages = 753–763 | date = July 2015 | pmid = 26040902 | doi = 10.1177/0269881115587958 | s2cid = 358375 | url = https://kclpure.kcl.ac.uk/portal/en/publications/dcd51fd9-ba02-4e7c-b84e-6b2086ae91af }}</ref>
* [[Vitamin B12|Vitamin B<sub>12</sub>]]{{snd}} no cognition-enhancing effects in middle-aged and older adults without B12 deficiency.<ref name="Systematic rev – B vitamins" />
* [[Vitamin B12|Vitamin B<sub>12</sub>]]{{snd}} no cognition-enhancing effects in middle-aged and older adults without B12 deficiency.<ref name="Systematic rev – B vitamins" />
* [[Vitamin B6|Vitamin B<sub>6</sub>]]{{snd}} no cognition-enhancing effects in middle-aged and older adults without B6 deficiency.<ref name="Systematic rev – B vitamins" />
* [[Vitamin B6|Vitamin B<sub>6</sub>]]{{snd}} no cognition-enhancing effects in middle-aged and older adults without B6 deficiency.<ref name="Systematic rev – B vitamins" />
Line 116: Line 94:
== See also ==
== See also ==
{{Portal|Medicine|Psychology}}
{{Portal|Medicine|Psychology}}
* [[Cognitive science]]
* [[Evidence-based learning]]
* ''[[Flowers for Algernon]]'', a novel on the subject of enhancing intelligence
* [[Human enhancement]]
* [[List of drugs used by militaries]]
* [[List of drugs used by militaries]]
* {{Section link|Neurobiological effects of physical exercise|Persistent effects on cognition}}
* {{Section link|Neurobiological effects of physical exercise|Transient effects on cognition}}
* [[Neuroenhancement]]
* [[Neuroenhancement]]
* [[Neuropharmacology]]
* [[Neuroplastic effects of pollution]]
* [[Neuropsychopharmacology]]
* [[Nutritional neuroscience]]
* [[Psychoactive drug]]
* [[Psychoactive drug]]



Revision as of 19:59, 15 April 2024

Illustration of Coffea arabica plant and seeds
Caffeine from the Coffea arabica plant is the world's most consumed nootropic.

Nootropics (/n.əˈtrpɪks/ noh-ə-TROHP-iks or /n.əˈtrɒpɪks/ noh-ə-TROP-iks;[1] but not /njˈtrpɪks/ new-TROHP-iks or /njˈtrɒpɪks/ new-TROP-iks,[1] which are common mispronunciations), colloquially brain supplements, smart drugs and cognitive enhancers, are natural, semisynthetic or synthetic compounds which purportedly improve cognitive functions, such as executive functions, attention or memory.

While commonly in the form of dietary supplements, nutraceuticals or energy drinks,[2] some nootropic compounds are prescription and non-prescription drugs in various countries.

In the United States, the Federal Trade Commission and FDA have warned manufacturers and consumers about possible advertising fraud and marketing scams concerning nootropic supplements.[3][4]

History of term

The term nootropic is derived from Ancient Greek νόος (nóos) 'mind', and τροπή (tropḗ) 'turning'.[1][5][6]

The first documented use of "nootropic" in reference to substances purported to increase cognitive functions was by Corneliu E. Giurgea in 1972.[5][6][7] When researching a new compound, Giurgea found a spectrum of effects that did not align with any psychotropic drug category, leading to his proposal of a new category and the concept of the term nootropic.[6]

Giurgea stated that nootropic drugs should have the following characteristics:

  1. They should enhance learning and memory.
  2. They should enhance the resistance of learned behaviors or memories to conditions which tend to disrupt them (e.g. electroconvulsive shock, hypoxia).
  3. They should protect the brain against various physical or chemical injuries.
  4. They should increase the efficacy of the tonic cortical control mechanisms.
  5. They should lack the usual pharmacology of other psychotropic drugs (e.g. sedation, motor stimulation) and possess few adverse effects and low toxicity.

However, there is no globally accepted or clinical definition of a nootropic. Most compounds described as nootropic do not correspond to Giurgea's characteristics.[7]

Unproven marketing claims

In the United States, nootropics are commonly advertised with unproven claims of effectiveness for improving cognition. Manufacturers' marketing claims for dietary supplements are usually not formally tested and verified by independent entities.[8] In 2019, the US FDA and FTC warned manufacturers and consumers about possible advertising fraud and marketing scams concerning nootropic supplement products.[3][4][9][10] The FDA and FTC stated that some nootropic products had not been approved as a prescription drug effective for any medical purpose, were not proven to be safe, and were illegally marketed in the United States under violation of the Federal Food, Drug, and Cosmetic Act.[3][4]

In 2018 in the United States, some nootropic supplements were identified as having misleading ingredients and illegal marketing.[11][12] In 2019, the FDA and FTC warned manufacturers and consumers about possible advertising fraud and marketing scams concerning nootropic supplements.[3][4]

Over the years 2010 to 2019, the FDA warned numerous supplement manufacturers about the illegal status of their products as unapproved drugs with no proven safety or efficacy at the doses listed on the products, together with misleading marketing.[3][4][9][10][13][14]

Availability and prevalence

In 2008, stimulants, such as caffeine, were the most commonly used nootropic agent.[15] In 2016, the American Medical Association adopted a policy to discourage prescriptions of nootropics for healthy people, on the basis that the cognitive effects appear to be highly variable among individuals, are dose-dependent, and limited or modest at best.[16] Piracetam, noopept and meclofenoxate have been sold as dietary supplements.[2][17][18]

Adverse effects

The main concern with pharmaceutical drugs and dietary supplements are adverse effects. Long-term safety evidence is typically unavailable for many nootropic compounds. Racetams, piracetam and other compounds that are structurally related to piracetam, have few serious adverse effects and low toxicity, but there is little evidence that they enhance cognition in people having no cognitive impairments.[19]

In the United States, dietary supplements may be marketed if the manufacturer can show that the supplement is generally recognized as safe, and if the manufacturer does not make any claims about using the supplement to treat or prevent any disease or condition; supplements that contain drugs or advertise health claims are illegal under US law.[20]

Types

Central nervous system stimulants

Systematic reviews and meta-analyses of clinical research using low doses of certain central nervous system stimulants found that these drugs may enhance cognition in healthy people.[21][22][23] In particular, the classes of stimulants that demonstrate possible cognition-enhancing effects in humans have evidence in vitro as direct agonists or indirect agonists of dopamine receptor D1 or adrenoceptor A2.[21][22][24][25] Relatively high doses of stimulants cause cognitive deficits.[24][25]

  • Amphetamine – systematic reviews and meta-analyses report that low-dose amphetamine may improve cognitive functions (e.g., inhibitory control, episodic memory, working memory, and aspects of attention) in healthy people and in individuals with ADHD.[21][22][23][25] A 2014 systematic review noted that low doses of amphetamine also improve memory consolidation, in turn leading to improved recall of information in non-ADHD youth.[23] It also improves task saliency (motivation to perform a task) and performance on tedious tasks that required a high degree of effort.[22][24][25]
  • Caffeine – a meta-analysis found an increase in alertness and attentional performance.[26][24]
  • Eugeroics (armodafinil and modafinil) – are classified as "wakefulness-promoting agents"; modafinil may increase alertness, particularly in sleep-deprived individuals, and may improve reasoning and problem solving in non-ADHD youth.[23] In a systematic review of small, preliminary studies where the effects of modafinil were examined, when simple psychometric assessments were considered, modafinil intake enhanced executive function.[27] Modafinil does not improve mood or motivation in sleep-deprived or non-sleep deprived individuals.[28]
  • Methylphenidate – a benzylpiperidine derivative that may improve working memory, episodic memory, and inhibitory control, aspects of attention, and planning latency in healthy people.[21][23] It also may improve task saliency and performance on tedious tasks.[25] At above optimal doses, methylphenidate has off–target effects that decrease learning.[29]
  • Nicotine – has been associated with improved alertness, attention, memory, and motor performance, according to a meta-analysis.[30] However, a 2020 systematic review raised concerns about potential conflicts of interest, noting industry funding in many studies and inconsistent results regarding nicotine's cognitive effects. This review found that over half of the studies published after 2010 had tobacco industry affiliations, often undisclosed.[31]

Racetams

Racetams, such as piracetam, oxiracetam, phenylpiracetam, and aniracetam, are often marketed as cognitive enhancers and sold over the counter.[2][17] A 2019 study found that piracetam supplements sold in the United States were inaccurately labeled.[17] Racetams are often referred to as nootropics, but this property is not well established in humans, and nootropics are not consistently found in all racetams.[32] The racetams have poorly understood mechanisms, although piracetam and aniracetam are known to act as positive allosteric modulators of AMPA receptors and appear to modulate cholinergic systems.[33]

According to the FDA,

Piracetam is not a vitamin, mineral, amino acid, herb or other botanical, or dietary substance for use by humans to supplement the diet by increasing the total dietary intake. Further, piracetam is not a concentrate, metabolite, constituent, extract or combination of any such dietary ingredient. [...] Accordingly, these products are drugs, under section 201(g)(1)(C) of the Act, 21 U.S.C. § 321(g)(1)(C), because they are not foods and they are intended to affect the structure or any function of the body. Moreover, these products are new drugs as defined by section 201(p) of the Act, 21 U.S.C. § 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling.[14]

Cholinergics

Some supposed nootropic substances are compounds and analogues of choline, a precursor of acetylcholine (a neurotransmitter) and phosphatidylcholine (a structural component of cell membranes).

  • Alpha-GPC – L-alpha glycerylphosphorylcholine has been studied only in the context of cognitive performance alongside other substances such as caffeine.[34]
  • Choline bitartrate – Choline bitartrate is a tartaric acid salt containing choline (41% choline by molecular weight). One meta-analysis found choline bitartrate to be ineffective at improving any measure of cognitive performance.[35]
  • Citicoline – Compound consisting of choline and cytidine. A meta-analysis found that it may be effective for improving memory and learning in older people with mild cognitive decline, and in people recovering from a stroke.[36][37]

Herbs

  • Centella asiatica – A 2017 meta-analysis showed no significant improvement in cognitive function.[38] Clinical efficacy and safety have not been scientifically confirmed for this herb.[39]
  • Ginkgo biloba – An extract of Ginkgo biloba leaf is marketed in dietary supplement form with claims it can enhance cognitive function in people without known cognitive problems, although there is no high-quality evidence to support such effects on memory or attention in healthy people.[40][41]
  • Panax ginseng – A Cochrane review found possible "improvement of some aspects of cognitive function, behavior and quality of life", but concluded that "there is a lack of convincing evidence to show a cognitive enhancing effect of Panax ginseng in healthy participants and no high quality evidence about its efficacy in patients with dementia."[42]

Nutrients and dietary supplements

  • Folate – no cognition-enhancing effects in middle-aged and older adults without folate deficiency.[43]
  • Omega-3 fatty acids: DHA and EPA – two Cochrane Collaboration reviews on the use of supplemental omega-3 fatty acids for ADHD and learning disorders conclude that there is limited evidence of treatment benefits for either disorder.[44][45] Two other systematic reviews found no cognition-enhancing effects in the general population.[43][46]
  • Vitamin B12 – no cognition-enhancing effects in middle-aged and older adults without B12 deficiency.[43]
  • Vitamin B6 – no cognition-enhancing effects in middle-aged and older adults without B6 deficiency.[43]
  • Vitamin E – no cognition-enhancing effects in middle-aged and older adults without vitamin E deficiency.[43]

See also

References

  1. ^ a b c "Nootropic". Oxford English Dictionary. 2024. Retrieved January 14, 2024.
  2. ^ a b c Cohen PA, Avula B, Wang YH, Zakharevich I, Khan I (June 2021). "Five Unapproved Drugs Found in Cognitive Enhancement Supplements". Neurology. Clinical Practice. 11 (3): e303–e307. doi:10.1212/CPJ.0000000000000960. PMC 8382366. PMID 34484905.
  3. ^ a b c d e "FTC and FDA Send Warning Letters to Companies Selling Dietary Supplements Claiming to Treat Alzheimer's Disease and Remediate or Cure Other Serious Illnesses Such as Parkinson's, Heart Disease, and Cancer". US Food and Drug Administration, US Federal Trade Commission. February 11, 2019. Retrieved May 11, 2019.
  4. ^ a b c d e "Health fraud scams: Unproven Alzheimer's disease products". US Food and Drug Administration. December 22, 2018. Retrieved May 11, 2019.
  5. ^ a b Giurgea C (1972). "[Pharmacology of integrative activity of the brain. Attempt at nootropic concept in psychopharmacology]". Actualites Pharmacologiques (in French). 25: 115–156. PMID 4541214.
  6. ^ a b c Giurgea C, Salama M (January 1, 1977). "Nootropic drugs". Progress in Neuro-Psychopharmacology. 1 (3): 235–247. doi:10.1016/0364-7722(77)90046-7. The term "nootropic" (noos = mind; tropein = towards) was proposed by us (Giurgea, 1972,1973) to designate psychotropic drugs
  7. ^ a b Malík M, Tlustoš P (August 2022). "Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs". Nutrients. 14 (16): 3367. doi:10.3390/nu14163367. PMC 9415189. PMID 36014874.
  8. ^ "Dietary Supplements: What You Need to Know". US Food and Drug Administration. Retrieved February 14, 2015.
  9. ^ a b Correll Jr WA (February 5, 2019). "FDA Warning Letter: Peak Nootropics LLC aka Advanced Nootropics". Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration. Retrieved May 11, 2019.
  10. ^ a b Correll Jr WA (February 5, 2019). "FDA Warning Letter: TEK Naturals". Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration. Retrieved May 11, 2019.
  11. ^ Schultz H (May 17, 2018). "Some shady ingredients find home in nootropics category". NutraIngredients-USA.com, William Reed Business Media Ltd. Retrieved May 11, 2019.
  12. ^ Heid M (January 23, 2019). "Nootropics, or 'Smart Drugs,' Are Gaining Popularity. But Should You Take Them?". Time. Retrieved May 12, 2019.
  13. ^ Singleton ER (January 7, 2010). "FDA Warning Letter: Cerebral Health LLC". Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration. Archived from the original on January 12, 2017. Retrieved May 12, 2019.
  14. ^ a b John Gridley (August 30, 2010). "FDA Warning Letter: Unlimited Nutrition". Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration. Archived from the original on January 12, 2017. Retrieved April 5, 2016.
  15. ^ Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, Farah MJ (December 2008). "Towards responsible use of cognitive-enhancing drugs by the healthy" (PDF). Nature. 456 (7223): 702–705. Bibcode:2008Natur.456..702G. doi:10.1038/456702a. OCLC 01586310. PMID 19060880. S2CID 3598099.
  16. ^ "AMA confronts the rise of nootropics". American Medical Association. June 14, 2016. Retrieved May 12, 2019.
  17. ^ a b c Cohen PA, Zakharevich I, Gerona R (March 2020). "Presence of Piracetam in Cognitive Enhancement Dietary Supplements". JAMA Internal Medicine. 180 (3): 458–459. doi:10.1001/jamainternmed.2019.5507. PMC 6902196. PMID 31764936.
  18. ^ Cohen PA, Avula B, Khan I (October 2022). "The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements". Clinical Toxicology. 60 (10): 1156–1158. doi:10.1080/15563650.2022.2109485. PMID 35959800. S2CID 251516603.
  19. ^ Malykh AG, Sadaie MR (February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders". Drugs. 70 (3): 287–312. doi:10.2165/11319230-000000000-00000. PMID 20166767. S2CID 12176745.
  20. ^ Goldman P (October 2001). "Herbal medicines today and the roots of modern pharmacology". Annals of Internal Medicine. 135 (8 Pt 1): 594–600. doi:10.7326/0003-4819-135-8_Part_1-200110160-00010. PMID 11601931. S2CID 35766876.
  21. ^ a b c d Spencer RC, Devilbiss DM, Berridge CW (June 2015). "The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex". Biological Psychiatry. 77 (11): 940–950. doi:10.1016/j.biopsych.2014.09.013. PMC 4377121. PMID 25499957.
  22. ^ a b c d Ilieva IP, Hook CJ, Farah MJ (June 2015). "Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis". Journal of Cognitive Neuroscience. 27 (6): 1069–1089. doi:10.1162/jocn_a_00776. PMID 25591060. S2CID 15788121.
  23. ^ a b c d e Bagot KS, Kaminer Y (April 2014). "Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review". Addiction. 109 (4): 547–557. doi:10.1111/add.12460. PMC 4471173. PMID 24749160.
  24. ^ a b c d Wood S, Sage JR, Shuman T, Anagnostaras SG (January 2014). "Psychostimulants and cognition: a continuum of behavioral and cognitive activation". Pharmacological Reviews. 66 (1): 193–221. doi:10.1124/pr.112.007054. PMC 3880463. PMID 24344115.
  25. ^ a b c d e Malenka RC, Nestler EJ, Hyman SE, Holtzman DM (2015). "14: Higher Cognitive Function and Behavioral Control". Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (3 ed.). New York: McGraw-Hill Medical. ISBN 9780071827706.
  26. ^ Camfield DA, Stough C, Farrimond J, Scholey AB (August 2014). "Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis". Nutrition Reviews. 72 (8): 507–522. doi:10.1111/nure.12120. PMID 24946991.
  27. ^ Battleday RM, Brem AK (November 2015). "Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review". European Neuropsychopharmacology. 25 (11): 1865–1881. doi:10.1016/j.euroneuro.2015.07.028. PMID 26381811. S2CID 23319688.
  28. ^ Mohamed AD (2017). "Does modafinil improve cognitive functioning in healthy individuals?". In ter Meulen R, Hall W, Mohammed AD (eds.). Rethinking Cognitive Enhancement. Oxford University Press. p. 116. ISBN 9780198727392.
  29. ^ Urban KR, Gao WJ (2014). "Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brain". Frontiers in Systems Neuroscience. 8: 38. doi:10.3389/fnsys.2014.00038. PMC 4026746. PMID 24860437.
  30. ^ Heishman SJ, Kleykamp BA, Singleton EG (July 2010). "Meta-analysis of the acute effects of nicotine and smoking on human performance". Psychopharmacology. 210 (4): 453–469. doi:10.1007/s00213-010-1848-1. PMC 3151730. PMID 20414766.
  31. ^ Pasetes SV, Ling PM, Apollonio DE (January 2020). "Cognitive performance effects of nicotine and industry affiliation: a systematic review". Substance Abuse: Research and Treatment. 14: 117822182092654. doi:10.1177/1178221820926545. ISSN 1178-2218. PMC 7271274. PMID 32547048.
  32. ^ Malenka RC, Nestler EJ, Hyman SE (2009). Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2 ed.). New York: McGraw-Hill Medical. p. 454. ISBN 9780071481274.
  33. ^ Gualtieri F, Manetti D, Romanelli MN, Ghelardini C (2002). "Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs". Current Pharmaceutical Design. 8 (2): 125–138. doi:10.2174/1381612023396582. PMID 11812254.
  34. ^ Parker AG, Byars A, Purpura M, Jäger R (September 21, 2015). "The effects of alpha-glycerylphosphorylcholine, caffeine or placebo on markers of mood, cognitive function, power, speed, and agility". Journal of the International Society of Sports Nutrition. 12 (Suppl 1): P41. doi:10.1186/1550-2783-12-S1-P41. ISSN 1550-2783. PMC 4595381.
  35. ^ Lippelt DP, van der Kint S, van Herk K, Naber M (June 24, 2016). "No Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults". PLOS ONE. 11 (6): e0157714. Bibcode:2016PLoSO..1157714L. doi:10.1371/journal.pone.0157714. PMC 4920398. PMID 27341028.
  36. ^ Fioravanti M, Buckley AE (September 2006). "Citicoline (Cognizin) in the treatment of cognitive impairment". Clinical Interventions in Aging. 1 (3): 247–251. doi:10.2147/ciia.2006.1.3.247. PMC 2695184. PMID 18046877.
  37. ^ Franco-Maside A, Caamaño J, Gómez MJ, Cacabelos R (October 1994). "Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer's disease". Methods and Findings in Experimental and Clinical Pharmacology. 16 (8): 597–607. PMID 7760585.
  38. ^ Puttarak P, Dilokthornsakul P, Saokaew S, Dhippayom T, Kongkaew C, Sruamsiri R, Chuthaputti A, Chaiyakunapruk N (September 2017). "Effects of Centella asiatica (L.) Urb. on cognitive function and mood related outcomes: A Systematic Review and Meta-analysis". Scientific Reports. 7 (1): 10646. Bibcode:2017NatSR...710646P. doi:10.1038/s41598-017-09823-9. PMC 5587720. PMID 28878245.
  39. ^ "Gotu kola". Drugs.com. January 23, 2023. Retrieved September 21, 2023.
  40. ^ Laws KR, Sweetnam H, Kondel TK (November 2012). "Is Ginkgo biloba a cognitive enhancer in healthy individuals? A meta-analysis". Human Psychopharmacology. 27 (6): 527–533. doi:10.1002/hup.2259. PMID 23001963. S2CID 6307491.
  41. ^ "Ginkgo". National Center for Complementary and Integrative Health, US National Institutes of Health. September 2016. Retrieved July 9, 2018.
  42. ^ Geng J, Dong J, Ni H, Lee MS, Wu T, Jiang K, Wang G, Zhou AL, Malouf R (December 2010). "Ginseng for cognition". The Cochrane Database of Systematic Reviews (12): CD007769. doi:10.1002/14651858.CD007769.pub2. PMID 21154383.
  43. ^ a b c d e Forbes SC, Holroyd-Leduc JM, Poulin MJ, Hogan DB (December 2015). "Effect of Nutrients, Dietary Supplements and Vitamins on Cognition: a Systematic Review and Meta-Analysis of Randomized Controlled Trials". Canadian Geriatrics Journal. 18 (4): 231–245. doi:10.5770/cgj.18.189. PMC 4696451. PMID 26740832.
  44. ^ Gillies D, Leach MJ, Perez Algorta G (April 2023). "Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents". The Cochrane Database of Systematic Reviews. 2023 (4): CD007986. doi:10.1002/14651858.CD007986.pub3. PMC 10103546. PMID 37058600.
  45. ^ Tan ML, Ho JJ, Teh KH (December 2012). Tan ML (ed.). "Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders". The Cochrane Database of Systematic Reviews. 12: CD009398. doi:10.1002/14651858.CD009398.pub2. PMID 23235675.
  46. ^ Cooper RE, Tye C, Kuntsi J, Vassos E, Asherson P (July 2015). "Omega-3 polyunsaturated fatty acid supplementation and cognition: A systematic review and meta-analysis". Journal of Psychopharmacology. 29 (7): 753–763. doi:10.1177/0269881115587958. PMID 26040902. S2CID 358375.

External links

Leave a Reply